Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials

PURPOSE: Selection bias in clinical trials has consequences for scientific validity and applicability of study results to the general population. There is concern that patients with clinically aggressive disease may not have enrolled in recent diffuse large B-cell lymphoma (DLBCL) trials due to the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Maurer, Matthew J., Ghesquières, Hervé, Link, Brian K., Jais, Jean-Philippe, Habermann, Thomas M., Thompson, Carrie A., Haioun, Corinne, Allmer, Cristine, Johnston, Patrick B., Delarue, Richard, Micallef, Ivana N., Peyrade, Frederic, Inwards, David J., Ketterer, Nicolas, Farooq, Umar, Fitoussi, Olivier, Macon, William R., Molina, Thierry J., Syrbu, Sergei, Feldman, Andrew L., Slager, Susan L., Weiner, George J., Ansell, Stephen M., Cerhan, James R., Salles, Gilles A., Witzig, Thomas E., Tilly, Hervé, Nowakowski, Grzegorz S.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2018
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5978469/
https://ncbi.nlm.nih.gov/pubmed/29672223
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.76.5198
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados